Related Experiment Video
Updated: Feb 20, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys
Yumei Xiong1, Kenneth Walker2, Xiaoshan Min3
1Department of Cardiometabolic Disorders, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
Abstract:
In search of metabolically regulated secreted proteins, we conducted a microarray study comparing gene expression in major metabolic tissues of fed and fasted ob/ob mice and C57BL/6 mice. The array used in this study included probes for ~4000 genes annotated as potential secreted proteins. Circulating macrophage inhibitory cytokine 1 (MIC-1)/growth differentiation factor 15 (GDF15) concentrations were increased in obese mice, rats, and humans in comparison to age-matched lean controls. Adeno-associated virus-mediated overexpression of GDF15 and recombinant GDF15 treatments reduced food intake and body weight and improved metabolic profiles in various metabolic disease models in mice, rats, and obese cynomolgus monkeys. Analysis of the GDF15 crystal structure suggested that the protein is not suitable for conventional Fc fusion at the carboxyl terminus of the protein. Thus, we used a structure-guided approach to design and successfully generate several Fc fusion molecules with extended half-life and potent efficacy. Furthermore, we discovered that GDF15 delayed gastric emptying, changed food preference, and activated area postrema neurons, confirming a role for GDF15 in the gut-brain axis responsible for the regulation of body energy intake. Our work provides evidence that GDF15 Fc fusion proteins could be potential therapeutic agents for the treatment of obesity and related comorbidities.
Insights
Growth differentiation factor 15 (GDF15) shows promise as an obesity treatment. GDF15 Fc fusion proteins effectively reduced body weight and improved metabolic health in preclinical models.
Area of Science:
- Metabolic research
- Endocrinology
- Obesity therapeutics
Background:
- Obesity is a complex metabolic disorder with limited effective treatments.
- Identifying metabolically regulated secreted proteins is crucial for therapeutic development.
Purpose of the Study:
- To investigate the role of macrophage inhibitory cytokine 1 (MIC-1)/growth differentiation factor 15 (GDF15) in metabolic regulation.
- To develop novel GDF15-based therapeutics for obesity and related conditions.
Main Methods:
- Microarray analysis of gene expression in metabolic tissues of lean and obese mice.
- Administration of adeno-associated virus-mediated GDF15 and recombinant GDF15 in preclinical models.
- Structure-guided design and generation of GDF15 Fc fusion proteins.
- Assessment of GDF15's effects on gastric emptying, food preference, and neuronal activation.
Main Results:
- Elevated circulating GDF15 levels were observed in obese mice, rats, and humans.
- GDF15 treatment reduced food intake, body weight, and improved metabolic profiles.
- Novel Fc fusion molecules of GDF15 demonstrated extended half-life and potent efficacy.
- GDF15 was found to influence the gut-brain axis by delaying gastric emptying and activating specific neurons.
Conclusions:
- GDF15 plays a significant role in regulating energy intake and body weight.
- GDF15 Fc fusion proteins represent a promising therapeutic strategy for obesity and its comorbidities.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients

